HIV-1 vaccine development: progress and prospects.
The development of a prophylactic HIV-1 vaccine is a global health priority. It has proven extraordinarily challenging, however, to develop immunogens that elicit broadly reactive HIV-1-specific neutralizing antibodies. As a result, most HIV-1 vaccine candidates in development focus on generating virus-specific cellular immune responses. Both plasmid DNA vaccines and recombinant live vectors have been shown to elicit cellular immune responses, and vaccine candidates based on these technologies are now being evaluated for safety, immunogenicity, and efficacy in advanced phase clinical trials. This review examines the progress and prospects of these vaccine strategies.
Thorner
Anna R
AR
Research East Room 213, Division of Viral Pathogenesis,Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215, USA.
Barouch
Dan H
DH